<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370536</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 40-5004</org_study_id>
    <nct_id>NCT03370536</nct_id>
  </id_info>
  <brief_title>ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization</brief_title>
  <official_title>Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivek Reddy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, non-randomized, un-blinded, observational trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, multicenter observational study will examine the ability of ECGi mapping to

        1. Effect of Ibutilide on the number and size of the driver domains

        2. Effect of ablation of Ibutilide-organized driver domains

        3. Effect of PV isolation on driver domains

      The researchers hypothesize that this approach will lead to successful arrhythmia control .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who no longer has recurrent At/AF</measure>
    <time_frame>at 12 months</time_frame>
    <description>Freedom from recurrent At/AF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of drivers</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of drivers identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of drivers</measure>
    <time_frame>Baseline</time_frame>
    <description>Size of drivers ablated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of driver regions</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Percent change of driver regions after ibutilide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF termination rate</measure>
    <time_frame>post abaltion inducibility of AF after 5 minutes of burst pacing</time_frame>
    <description>AF termination rate is defined as AF termination to AT/SR (Atrial Tachycardia/Sinus Rhythm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>within 24 hours after the procedure is completed the time is calculated</time_frame>
    <description>Total duration of RF ablation/fluoroscopy time/exposure procedure time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients with AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with AF and planned to undergo first catheter procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioInsight ECGI Mapping System</intervention_name>
    <description>The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.</description>
    <arm_group_label>Patients with AF</arm_group_label>
    <other_name>ECGi mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF ablation</intervention_name>
    <description>Empiric ablation (CFAE or linear ablation) is not permitted</description>
    <arm_group_label>Patients with AF</arm_group_label>
    <other_name>Biosense Thermocool SF</other_name>
    <other_name>Biosense Smart Touch SF (STSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibutilide</intervention_name>
    <description>Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)</description>
    <arm_group_label>Patients with AF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age.

          -  ° Symptomatic persistent AF refractory or intolerant to at least 1 class I or III
             antiarrhythmic medication Persistent AF - defined as Persistent: AF that is sustained
             &gt; 7 days. Episodes of AF which are terminated by electrical or pharmacologic
             cardioversion after ≥ 48 hours of AF, but prior to 7 days, should also be classified
             as persistent AF episodes.

               -  Planned to undergo first catheter ablation procedure ( prior atrial flutter
                  typical is allowed)

          -  Ability to understand the requirements of the study and sign the informed consent
             form.

          -  Willingness to adhere to study restrictions and comply with all post-procedural
             follow-up requirements

          -  Projected lifespan greater than 1 year

        Exclusion Criteria:

          -  They have baseline prolonged QT or renal failure precluding safe used of ibutilide

          -  Rheumatic heart disease,

          -  Current intra-cardiac thrombus,

          -  History of MI or CABG within 6 weeks;

          -  Class IV HF,

          -  Unable to sign consent

          -  Projected lifespan of &lt; 1 year

          -  Women known to be pregnant or to have positive beta-HCG.

          -  Participation in another study that would interfere with this study.

          -  Unstable Angina

          -  Recent cerebral ischemic events

          -  Contraindication to anticoagulation

          -  Prior history of polymorphic ventricular tachycardia or torsades de pointes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Koruth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Harcum, BA</last_name>
    <phone>212-824-8927</phone>
    <email>stephanie.harcum@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betsy Ellsworth</last_name>
    <phone>212-824-8902</phone>
    <email>betsy.ellsworth@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Harcum</last_name>
      <phone>212-824-8924</phone>
      <email>stephanie.harcum@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Jason Koruth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Vivek Reddy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <keyword>AFIB</keyword>
  <keyword>Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibutilide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

